What is the difference between Renflexis and Remicade?
Medically reviewed by Drugs.com Last updated on Sep 16, 2019.
Official Answerby Drugs.com
According to the FDA, a biosimilar must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product -- in this case Remicade. Only minor differences in clinically inactive components are allowable in biosimilar products.
Renflexis is given as an intravenous infusion similar to Remicade, and is indicated for the same indications, specifically treatment of Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
The first biosimilar to Remicade, Pfizer’s Inflectra (infliximab-dyyb) was approved by the FDA in April, 2016.
For more information, see Comparing Remicade vs Renflexis
Related Medical Questions
- What is the difference between Inflectra and Remicade?
- What is the difference between Ixifi and Remicade?
- How many biosimilars have been approved in the United States?
- What are the new drugs for the treatment of plaque psoriasis?
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?